Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Antares Pharma (ATRS)

Antares Pharma (ATRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Antares Pharma to Present at the Ladenburg Thalmann 2019 Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September...

ATRS : 3.46 (unch)
Teva Announces Availability of a Generic Equivalent of EpiPen Jr(R) (epinephrine injection, USP) Auto-Injector, 0.15 mg in the United States

Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced availability of the FDA-approved generic version of EpiPen Jr(R)(1) (epinephrine injection, USP) Auto-Injector, 0.15 mg, in the U.S....

TEVA : 7.50 (-3.47%)
ATRS : 3.46 (unch)
Antares Pharma: 2Q Earnings Snapshot

EWING, N.J. (AP) _ Antares Pharma Inc. (ATRS) on Tuesday reported a loss of $2.2 million in its second quarter.

ATRS : 3.46 (unch)
Antares Pharma Reports Second Quarter 2019 Operating and Financial Results

Record Quarterly Revenue of $28.4 Million - Double Second Quarter 2018 Revenue

ATRS : 3.46 (unch)
Antares Pharma to Report Second Quarter 2019 Financial and Operating Results

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its second quarter 2019 financial results and recent operating progress before the market opens on Tuesday, August 6, 2019. Management...

ATRS : 3.46 (unch)
Needle Free Drug Delivery Devices Market is expanding steadily at a CAGR of 9.90% till 2023, Noted TMR

Healthcare industry across the globe is booming due to increasing importance on saving life and ensuring every person to get adequate healthcare facilities. Governments are also taking significant and...

ATRS : 3.46 (unch)
ZGNX : 42.59 (-4.53%)
Antares Pharma Announces Amendment to Existing Loan and Security Agreement With Hercules Capital

Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares" or "the Company") today announced that it has entered into an amendment to its existing loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC),...

ATRS : 3.46 (unch)
HTGC : 13.44 (-0.81%)
Antares Pharma to Present at the B. Riley FBR Institutional Investor Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Fred M. Powell, Executive Vice President and Chief Financial Officer, will present at the B. Riley FBR Institutional Investor Conference on Thursday...

ATRS : 3.46 (unch)
Antares Pharma: 1Q Earnings Snapshot

EWING, N.J. (AP) _ Antares Pharma Inc. (ATRS) on Thursday reported a loss of $5.5 million in its first quarter.

ATRS : 3.46 (unch)
Antares Pharma Reports First Quarter 2019 Operating and Financial Results

Antares Pharma, Inc. (NASDAQ: ATRS) ("the Company") today reported operating and financial results for the first quarter ended March 31, 2019. The Company reported revenue of $23.3 million and a net loss...

ATRS : 3.46 (unch)
Antares Pharma to Report First Quarter 2019 Financial and Operating Results

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its first quarter 2019 financial results and recent operating progress before the market opens on Thursday, May 2, 2019. Management...

ATRS : 3.46 (unch)
Transdermal/Transmucosal Drug Delivery System Market Size, Growth Opportunities, Trends by Manufacturers, Regions, Application & Forecast to 2024

Market Study Report newly added the Global Transdermal/Transmucosal Drug Delivery System Market Report that gives meticulous investigation of current scenario of the market size, share, demand, growth,...

ATRS : 3.46 (unch)
CORI : 12.68 (+0.24%)
DRRX : 1.99 (+1.53%)
ZSAN : 1.92 (-1.54%)
New Research: Key Drivers of Growth for Progress Software, Antares Pharma, National Vision, NMI, Waters, and Kelly Services -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Progress Software Corporation...

KELYB : 26.46 (-0.49%)
PRGS : 39.36 (-3.17%)
ATRS : 3.46 (unch)
EYE : 22.99 (-3.81%)
NMIH : 27.82 (-0.61%)
WAT : 215.75 (+0.46%)
KELYA : 23.17 (-0.34%)
Antares Pharma Announces Receipt of Orphan Drug Designation for the Treatment of Ectopic Pregnancy With Methotrexate

Antares Pharma, Inc. (NASDAQ: ATRS) today announced receipt of orphan drug designation to evaluate the use of subcutaneous methotrexate ("MTX") for the treatment of ectopic pregnancy that meets predefined...

ATRS : 3.46 (unch)
AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study

Shares of AMAG (AMAG) decline almost 17% after the company's pregnancy drug, Makena fails in the post approval PROLONG study.

AMAG : 11.20 (-1.88%)
CELG : 102.95 (+1.13%)
BDSI : 5.16 (+0.19%)
ATRS : 3.46 (unch)
Antares Pharma to Present at the Cowen and Company 39th Annual Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Cowen and Company 39 Annual Healthcare Conference on Wednesday March...

ATRS : 3.46 (unch)
Antares Pharma Appoints Dr. Karen Smith to Board of Directors and Announces Retirement of Dr. Jacques Gonella

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Dr. Karen Smith to the Company's Board of Directors, filling the seat being vacated by the retirement of Dr. Jacques Gonella. Dr....

ATRS : 3.46 (unch)
Antares Pharma Reports Fourth Quarter and Full Year 2018 Operating and Financial Results

Record Annual Revenue of $63.6 Million, a 17% Increase Over 2017 Revenue

ATRS : 3.46 (unch)
CERC : 3.39 (-2.31%)
BDSI : 5.16 (+0.19%)
Antares Pharma to Present at the Raymond James & Associates 40th Annual Institutional Investors Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James & Associates 40 Annual Institutional Investors Conference...

ATRS : 3.46 (unch)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +4.48 , AIZ -0.27 , SBAC +4.06 , SO +0.08 , WELL +0.91
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar